

**Section A6.1.3 Acute Toxicity****Annex Point IIA6.1 6.1.3 Acute inhalation toxicity to the rat (LC<sub>50</sub> Test)**

		<b>1 REFERENCE</b>	
<b>1.1 Reference</b>		██████████, 1988, KUE 13032C 90 VM 1146 B- Study for acute inhalation toxicity to the rat according to OECD guideline no. 403, ██████████, Report No. ██████████, 1988-03-07 (unpublished)	
<b>1.2 Data protection</b>		Yes	
1.2.1 Data owner		Bayer CropScience AG	
1.2.2 Companies with letter of access		Bayer Chemicals AG	
1.2.3 Criteria for data protection		Data submitted to the MS after 13 May 2000 on existing a.s. for the purpose of its entry into Annex I/IA.	
		<b>2 GUIDELINES AND QUALITY ASSURANCE</b>	
<b>2.1 Guideline study</b>		Yes	
		- OECD-Guideline No. 403	
		- EC Guideline B.2 and the EPA (FIFRA) Guideline § 81-3.	
<b>2.2 GLP</b>		Yes	
<b>2.3 Deviations</b>		No	
		<b>3 MATERIALS AND METHODS</b>	
<b>3.1 Test material</b>		As given in section 2 of dossier.	
3.1.1 Lot/Batch number		██████████	
3.1.2 Specification		As given in section 2 of dossier.	
3.1.2.1 Description		White powder with slight intrinsic odour.	
3.1.2.2 Purity		██████████	
3.1.2.3 Stability		The stability was assured over the period of the study (Analysis: July 15, 1986).	
<b>3.2 Test Animals</b>			
3.2.1 Species		Rat	
3.2.2 Strain		Wistar (Bor:WISW)	
3.2.3 Source		████████████████████	
3.2.4 Sex		Males and females (1:1)	
3.2.5 Age/weight at study initiation		Age: 7-12 weeks Weight: 160-220 g	
3.2.6 Number of animals per group		5 per sex per dose	
3.2.7 Control animals		Yes (air control)	

Official  
use only

**Section A6.1.3 Acute Toxicity****Annex Point IIA6.1 6.1.3 Acute inhalation toxicity to the rat (LC<sub>50</sub> Test)**

<b>3.3 Administration/ Exposure</b>	Inhalation
3.3.1 Postexposure period	14 days
3.3.2 Concentrations	For technical reasons, it is impossible to specify exact nominal concentrations. Analytical concentrations: 0, 94.7, 506.7, 1526.7, 2580 [mg/m <sup>3</sup> ]
3.3.3 Particle size	MMAD (mass median aerodynamic diameter) ± GSD (geometric standard deviation) for the dust : 94.7 mg/m <sup>3</sup> air: MMAD = 4.8 µm (± 1.79µm) 506.7 mg/m <sup>3</sup> air: MMAD = 5.47 µm (± 1.74µm) 1526.7 mg/m <sup>3</sup> air: MMAD = 5.78 µm (± 1.8µm) 2580 mg/m <sup>3</sup> air: MMAD = 6.0 µm (± 1.59µm)
3.3.4 Type or preparation of particles	The dust-containing atmosphere was generated by using a "██████ dust generator" or with an RBG 1000 brush-type dust generator.
3.3.5 Type of exposure	Nose/head only
3.3.6 Vehicle	—
3.3.7 Concentration in vehicle	—
3.3.8 Duration of exposure	4 h
3.3.9 Controls	Controls were exposed to air under the same conditions as the treatment groups.
<b>3.4 Examinations</b>	Clinical observations, necropsy, body weight.
<b>3.5 Method of determination of LC<sub>50</sub></b>	LC <sub>50</sub> calculation is performed according to the method of A. P. Rosiello, J. M. Essigmann and G. N. Wogan, as modified by Pauluhn. This procedure is based on the "maximum likelihood" method of C.I. Bliss.

**4 RESULTS AND DISCUSSION**

<b>4.1 Clinical signs</b>	After treatment with 0.095, 0.5, 1.5 and 2.58 mg/l air, males and females showed signs of dyspnoea, laboured breathing, respiratory noises, reduced motility, serosanguineous nasal discharge, languor and blood-encrusted eyes, periorbital hair loss and corneal opacity (only after dosing with 1.5 mg/l air), rough fur, and blood encrusted nose margins (only observed in the 2.58 mg/l dose-group).
<b>4.2 Pathology</b>	Gross pathological examinations of the 0.095 mg/l and the 0.5 mg/l group rats sacrificed at the end of the observation period gave no indications of macroscopically apparent organ damage. The frequent presence of distended lungs was not considered to be toxicologically significant since a clear concentration dependency could not be established.

The following significant findings were determined in the rats which died during the observation time (treatment groups from

**Section A6.1.3****Acute Toxicity****Annex Point IIA6.1**6.1.3 Acute inhalation toxicity to the rat (LC<sub>50</sub> Test)

		0.5 to 2.58 mg/l): markedly distended lung with partially hepatoid appearance; serous fluid in thorax and lungs; liver, spleen, and kidney pale; contents of gastrointestinal tract yellowish-mucid, also bloody isolated cases; glandular stomach inflamed; bloody-encrusted eyes, and corneal opacity.	
4.3	<b>Other</b>	A toxicologically significant, substance-induced effect on the body weights during the observation period was determined starting with the 1.5 mg/l treatment group.	X
4.4	<b>LC<sub>50</sub></b>	LC <sub>50</sub> approximately 1.2 mg/l air for males + females.	
<b>5 APPLICANT'S SUMMARY AND CONCLUSION</b>			
5.1	<b>Materials and methods</b>	The method used to perform the study complied with the OECD-Guideline No. 403 and with the EC Guideline B.2 and the EPA (FIFRA) Guideline § 81-3.  A study for acute inhalation toxicity in the rat was conducted with the test substance dichlofluanid.  The purpose of the study was to enable the product to be classified (labelling), and to assess the potential acute health hazard when handling the substance.	
5.2	<b>Results and discussion</b>	The observed clinical signs (starting with the 0.5 mg/l treatment group) as well as the pathological findings were considered to be related to the pronounced respiratory tract irritation potential of the test substance. The no-observed-effect-level was 0.095 mg/l air.	
5.3	<b>Conclusion</b>	The study results demonstrate that an elevated acute hazard potential for humans exists when the product (powder) is handled due to its mucous membrane irritation potential.  LC <sub>50</sub> approximately 1.200 mg/l air for males + females.	
5.3.1	Reliability	1	
5.3.2	Deficiencies	No	

**Section A6.1.3 Acute Toxicity****Annex Point IIA6.1** 6.1.3 Acute inhalation toxicity to the rat (LC<sub>50</sub> Test)

<b>Evaluation by Competent Authorities</b>	
Use separate "evaluation boxes" to provide transparency as to the comments and views submitted	
<b>EVALUATION BY RAPPORTEUR MEMBER STATE</b>	
<b>Date</b>	20/09/04
<b>Materials and Methods</b>	As described above. [IUCLID 5.1.2 1/3]
<b>Results and discussion</b>	Deaths occurred at concentrations of 0.5 mg/l and above, from day 0-day-3 post exposure.
<b>Conclusion</b>	As described above
<b>Reliability</b>	1
<b>Acceptability</b>	Acceptable
<b>Remarks</b>	The UK CA broadly agrees with the applicants' summary and conclusions. The UK CA has added some additional information on the mortalities observed in the study.
<b>COMMENTS FROM ...</b>	
<b>Date</b>	
<b>Materials and Methods</b>	
<b>Results and discussion</b>	
<b>Conclusion</b>	
<b>Reliability</b>	
<b>Acceptability</b>	
<b>Remarks</b>	

**Table A6\_1-1.3 Table for acute inhalation toxicity**

Dose [mg/m <sup>3</sup> air]	Toxicological results*	Duration of clinical signs	Time of death	Mortality (%)	Particles ≤ 5 µm (%)
<b>males</b>					
0	0/0/5	—	—	—	—
94.7	0/0/5	—	—	—	53
506.7	0/5/5	4h – 13d	—	—	44
1526.7	1/5/5	4h – 10d	1d	20	41
2580.0	5/5/5	4h – 3d	0d – 3d	100	35
LC <sub>50</sub> value approximately 1200 mg/m <sup>3</sup> air					

**Section A6.1.3 Acute Toxicity****Annex Point IIA6.1 6.1.3 Acute inhalation toxicity to the rat (LC<sub>50</sub> Test)**

females					
0	0/0/5	—	—	—	—
94.7	0/0/5	—	—	—	53
506.7	2/5/5	4h – 4d	1d – 2d	40	44
1526.7	2/5/5	4h – 14d	0d – 3d	40	41
2580.0	5/5/5	4h – 3d	0d – 3d	100	45
LC <sub>50</sub> value approximately 1200 mg/m <sup>3</sup> air					

\*first number = number of dead animals

second number = number of animals with signs

third number = number of animals used